US Patent Issued to Cancer Research Technology, The Institute of Cancer Research: Royal Cancer Hospital on Jan. 20 for "[1,4oxazepino[2,3-cquinolinone derivatives as BCL6 inhibitors" (British Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,826, issued on Jan. 20, was assigned to Cancer Research Technology Ltd. (London) and The Institute of Cancer Research: Royal Cancer Hospital (London).

"[1,4oxazepino[2,3-cquinolinone derivatives as BCL6 inhibitors" was invented by Benjamin Richard Bellenie (London), Alfie Brennan (London), Kwai Ming Jack Cheung (London), Owen Alexander Davis (London), Alice Claire Harnden (London), Swen Hoelder (London) and Rosemary Huckvale (London).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparat...